PT Bundamedik Tbk

As of June 30, 2026, PT Bundamedik Tbk carries a market capitalization of 1.52T, placing it among publicly traded companies globally. Its enterprise value stands at 3.22T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

PT Bundamedik Tbk's next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, PT Bundamedik Tbk has 8.60B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.94, and the price-to-book ratio stands at 0.78.

As of June 30, 2026, PT Bundamedik Tbk trades at an EV/EBITDA multiple of 18.10 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.98 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 51.76 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 3.22T versus a market cap of 1.52T, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, PT Bundamedik Tbk maintains a current ratio of 1.71, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 62.88, indicating elevated leverage, while an interest coverage ratio of 2.81 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, PT Bundamedik Tbk posted a negative return on equity (ROE) of -0.06, meaning shareholder capital produced losses rather than profits. Return on invested capital (ROIC) comes in at 0.26 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) is negative at -0.03, reflecting losses generated across the asset base. Return on capital employed (ROCE) is 0.15, useful for judging operating efficiency across full business cycles. The company generates approximately 1.04B in revenue per employee across its workforce of 1,563.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 20.30 indicates how many times PT Bundamedik Tbk sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, PT Bundamedik Tbk recorded 10.97B in income tax expense. That works out to an effective tax rate of 84.76, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 12.95B, leaving -1.09B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, PT Bundamedik Tbk's stock has gained approximately 28.39% over the past 52 weeks. The 50-day moving average sits at 196.66, while the 200-day moving average is 189.42.

Over the twelve months ended June 30, 2026, PT Bundamedik Tbk generated 1.62T in revenue and converted that into -1.09B in net income, yielding earnings per share of 0.23. EBITDA reached 178.04B, while operating income came in at 95.01B.

As of June 30, 2026, PT Bundamedik Tbk holds 237.22B in cash and equivalents against 1.50T in total debt, resulting in a net debt position of 1.16T. Total book value stands at 1.94T, with working capital of 513.33B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, PT Bundamedik Tbk posted a gross margin of 46.42, reflecting its pricing power and cost economics. The operating margin of 5.85 and net profit margin of -0.07 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, PT Bundamedik Tbk paid dividends of 0.57 per share. The dividend payout ratio of 97.70 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -9.52, meaning PT Bundamedik Tbk raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, PT Bundamedik Tbk has an Altman Z-Score of 1.26, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.